Research

Mixed

Noninvasive steatosis biomarkers (FLI, NAFLD-LFS, HSI, VAI, TyG) accurately diagnose the presence of hepatic steatosis but fail to quantify its severity, rendering them unsuitable for monitoring treatment-induced changes in liver fat.

Use these biomarkers (FLI, HSI, VAI, TyG) as a screening tool to identify who likely has fatty liver, especially if ultrasound isn't available. Do not use them to track if your diet or medication is working, as they cannot accurately measure how much fat is actually in the liver. They are good for 'rule-in' screening, not 'monitoring' treatment.

GoodQualifiesHIGH confidence
All five steatosis biomarkers can diagnose steatosis... However, their ability to quantify steatosis was poor: none of them distinguished between moderate and severe steatosis... this may limit their clinical utility.
Larysa Fedchuk et al. · Alimentary Pharmacology & Therapeutics · 2014

Why this rating

Large cohort (n=324), biopsy-validated, head-to-head comparison of 5 biomarkers.

Source

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

Larysa Fedchuk et al. · Alimentary Pharmacology & Therapeutics · 2014

DOI 10.1111/apt.12963

cohort · n=324Cited 509×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →